Moore Capital Management’s Akero Therapeutics AKRO Stock Holding History

Moore Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,931	Closed	-$255K	–	427
2023 Q3	$654K	Sell	12,931 -33,908	-72%	-$1.58M	0.01%	325
2023 Q2	$2.19M	Buy	+46,839	New	+$2.15M	0.04%	248
2019 Q3	–	Sell	-10,000	Closed	-$192K	–	307
2019 Q2	$192K	Buy	+10,000	New	+$190K	﹤0.01%	295

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Moore Capital Management's AKRO Position: Q4 2023 in Review

Moore Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 12,931 shares — an estimated $255K sold.

Moore Capital Management first reported a position in AKRO in Q2 2019 and held it in 3 quarters. The position peaked at $2.19M in Q2 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

Moore Capital Management reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
Moore Capital Management sold 12,931 Akero Therapeutics shares in Q4 2023, an estimated $255K.
Moore Capital Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 3 quarters.
Moore Capital Management's Akero Therapeutics position peaked at $2.19M in Q2 2023.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.